CTXR - キティウス・ファ―マシュ―ティカルズ (Citius Pharmaceuticals Inc.) キティウス・ファ―マシュ―ティカルズ

 CTXRのチャート


 CTXRの企業情報

symbol CTXR
会社名 Citius Pharmaceuticals Inc (キティウス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Citius Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products adjunctive cancer care and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30 2016 the Company had not generate any revenues.   キティウス・ファ―マシュ―ティカルズは米国の特殊医薬品メ―カ―。抗感染症薬、がん補助療法、処方薬に焦点を置いた治療薬の開発や商品化に従事する。開発中の薬剤には、カテ―テル関連血流感染を対象とした抗菌薬ロックソリュ―ション「Mino-Lok」や、痔核治療での炎症や麻酔痛を軽減するヒドロコルチゾン-リドカイン局所製剤がある。本社所在地はニュ―ジャ―ジ―州。   Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
本社所在地 11 Commerce Drive First Floor Cranford NJ 07016 USA
代表者氏名 Leonard L. Mazur Leonard L. Mazur
代表者役職名 Executive Chairman of the Board Secretary
電話番号 +1 908-967-6677
設立年月日 40422
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 7人
url www.citiuspharma.com
nasdaq_url https://www.nasdaq.com/symbol/ctxr
adr_tso
EBITDA EBITDA(百万ドル) -12.52810
終値(lastsale) 1.7899
時価総額(marketcap) 28994216.0109
時価総額 時価総額(百万ドル) 27.69993
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 25.11109
当期純利益 当期純利益(百万ドル) -12.73298
決算概要 決算概要 BRIEF: For the nine months ended 30 June 2018 Citius Pharmaceuticals Inc revenues was not reported. Net loss increased 32% to $9.7M. Higher net loss reflects Research and Development increase of 96% to $4.8M (expense) General and administrative increase of 8% to $4.7M (expense) Gain/Loss on Derivatives - Hedging decrease from $309K (income) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$1.48 to -$1.01.

 CTXRのテクニカル分析


 CTXRのニュース

   First Patient Dosed in Citius Pharma''s Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids  2022/04/26 15:56:00 Benzinga
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids. The Phase 2b clinical study is a multi-center, randomized, dose-ranging, double-blind, parallel group comparison clinical trial. Citius Pharma is planning to dose five cohorts of adults with a clinical diagnosis of … Full story available on Benzinga.com
   Citius Pharmaceuticals Inc. (NASDAQ: CTXR): Stock Plunge On The Way?  2022/04/19 14:00:00 Stocks Register
The trading price of Citius Pharmaceuticals Inc. (NASDAQ:CTXR) closed lower on Monday, April 18, closing at $1.47, -5.16% lower than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it fluctuated between $1.47 … Citius Pharmaceuticals Inc. (NASDAQ: CTXR): Stock Plunge On The Way? Read More »
   Citius Pharmaceuticals to Present at the NobleCon18 Investor Conference on April 20, 2022  2022/04/14 13:25:00 Benzinga
CRANFORD, N.J. , April 14, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at NobleCon18, Noble Capital Markets'' 18th Annual Investor Conference being held April 19-21, 2022 . Leonard Mazur , Executive Chairman of Citius, will discuss recent business developments and upcoming milestones. NobleCon18 Conference Date: Wednesday, April 20, 2022 at 1:30 p.m. EST Breakout sessions: … Full story available on Benzinga.com
   Citius Pharma realigns management to support commercialization of two late-stage products  2022/04/13 14:21:14 Seeking Alpha
Citius Pharmaceuticals (CTXR) on Wednesday announced a management realignment that the company says will help it focus its resources on advancing the commercialization of its I/ONTAK…
   Critical Care Biopharma - Citius Pharmaceuticals  2022/04/13 13:30:09 Seeking Alpha
Citius Pharmaceuticals is a late-stage biopharma focused on critical care products. Preventing shareholder dilution.
   FDA Signs Off Citius Pharma''s Phase 2 Trial With Halo-Lido In Hemorrhoids  2022/02/15 16:26:23 Benzinga
The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc''s (NASDAQ: CTXR ) Halo-Lido to treat hemorrhoids. The Company anticipates initiating a Phase 2b study in 1H of 2022. Halo-Lido is a proprietary topical formulation of halobetasol and lidocaine intended to provide symptomatic relief to individuals … Full story available on Benzinga.com
   Thinking about buying stock in Orphazyme, Yelp, Tritium DCFC, Blade Air Mobility, or Citius Pharmaceuticals?  2022/02/11 14:31:00 Benzinga
NEW YORK , Feb. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORPH, YELP, DCFC, BLDE, and CTXR. … Full story available on Benzinga.com
   Citius Pharmaceuticals GAAP EPS of -$0.06 in-line  2022/02/10 22:15:40 Seeking Alpha
Citius Pharmaceuticals press release (CTXR): FQ1 GAAP EPS of -$0.06 in-line.Cash and cash equivalents of $65.4M."We anticipate 2022 will be a year of important catalysts for Citius
   Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2022 Financial Results and Provides Business Update  2022/02/10 21:30:00 Benzinga
CRANFORD, N.J. , Feb. 10, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today reported business and financial results for the first fiscal quarter of 2022 ended December 31, 2021 . Fiscal Q1 2022 Business Highlights and Subsequent Developments Pivotal Phase 3 trial of I/ONTAK (E7777) completed in December 2021 with topline results anticipated in the first half of 2022 and a biologics license application (BLA) submission planned in the second half of 2022; Mino-Lok ® Phase 3 trial completion anticipated in 2022; and, Regulatory, manufacturing, clinical and commercial capabilities expanded to support late-stage pipeline with the addition of seasoned executives with extensive pharmaceutical industry experience: Catherine Kessler MS – EVP, Regulatory Affairs Kelly Creighton , PhD – EVP, Chemistry, Manufacturing and Controls Kevin Carey – VP, Program Management Preeti Singh , MD – Medical Director Financial Highlights Cash and cash equivalents of $65.
   Citius Pharmaceuticals reports FY results  2021/12/15 21:41:45 Seeking Alpha
   Citius Pharmaceuticals reports FY results  2021/12/15 21:41:45 Seeking Alpha
   Citius Pharmaceuticals Completes Enrollment in the Pivotal Phase 3 Study of its Cancer Immunotherapy I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma  2021/12/06 14:15:00 PR Newswire
CRANFORD, N.J., Dec. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective
   Up to Date Stock in Review: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), ENDRA Life Sciences Inc. (NASDAQ:NDRA)  2021/11/23 11:52:53 Stock Equity
Citius Pharmaceuticals, Inc. (CTXR) with the stream of -2.05% also noticed, India ENDRA Life Sciences Inc. (NDRA) encountered a rapid change of -9.11% in the last hour of Monday’s trading … The post Up to Date Stock in Review: Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), ENDRA Life Sciences Inc. (NASDAQ:NDRA) appeared first on Stocks Equity .
   Citius Pharmaceuticals (NASDAQ:CTXR) Stock Rating Upgraded by Zacks Investment Research  2021/11/11 08:40:41 Dakota Financial News
Citius Pharmaceuticals (NASDAQ:CTXR) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective []
   Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls  2021/11/05 13:15:00 PR Newswire
CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective

 関連キーワード  (医薬品 米国株 キティウス・ファ―マシュ―ティカルズ CTXR Citius Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)